Clinical trial
Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)
NCT02606877 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 19, 2016
- Completion date
- March 22, 2017
- Enrollment
- 37 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.